NCT06605326View on ClinicalTrials.gov

Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2024

Conditions
Pulmonary HypertensionPulmonary Arterial HypertensionChronic Lung Disease-Associated Pulmonary HypertensionLung TransplantationHeart Failure
Interventions
DRUG

Subcutaneous Treprostinil

Patients in this group received subcutaneous treprostinil, starting at a dose of 1.25 to 4 ng/kg/min and gradually titrated according to patient response. The target dose was over 20 ng/kg/min after 3 months of treatment. All patients were referred for lung transplantation during or after treprostinil treatment.

All Listed Sponsors
lead

Guangzhou Institute of Respiratory Disease

OTHER

NCT06605326 - Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study | Biotech Hunter | Biotech Hunter